DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

UTHR·United Therapeutics Corporation

$.
-. (-.%)
After Hours
High
$553.86
Open
$553.86
Market Cap
23.18B
52W High
$609.35
Low
$539.33
P. Close
$547.06
P/E
18.00
52W Low
$272.12
Fwd P/E
16.56
DailyIQ Est.
$687.73
Technical Score (1D)
41
SELL
News Sentiment
53
MIXED
BofA Securities lowered its price target for United Therapeutics from $620 to $613, citing a modestly weaker near‑term earnings outlook. The downgrade signals a slight shift in analyst sentiment that could temper investor enthusiasm in the coming week. In the same window, CEO Martine A. Rothblatt sold 9,500 shares worth about $5.2 million, the largest insider transaction this year, though no reason was disclosed. The timing of the sale, just days after the target adjustment, raises questions about insider confidence and may add short‑term volatility. Earlier this week, the company reported clinical wins for Tyvaso and ralinepag and progress in organ manufacturing, which had driven a 14 % YTD gain and bolstered long‑term growth expectations. The positive TETON‑1 phase III results for IPF and the planned expansion of Tyvaso into IPF and PPF markets further strengthen the pipeline narrative. Over the next 1–10 trading days, traders should watch how the market digests the price‑target cut and the CEO’s share sale, as both could influence short‑term sentiment. Additionally, keep an eye on any forthcoming earnings guidance that may confirm or refute the modest earnings concerns cited by BofA. Finally, monitor competitor launches in the PAH space and any regulatory updates on Tyvaso’s expanded indications, as these could materially affect UTHR’s valuation.
Earnings Summary
United Therapeutics Corporation is a biotechnology firm specializing in therapies for pulmonary arterial hypertension and other high‑margin indications, with a portfolio that includes Tyvaso, Remodulin, and Unituxin, and a growing pipeline of novel agents such as Ralinepag and Aurora‑GT. The company operates within the specialty drug manufacturing sector, focusing on niche, life‑saving treatments that command premium pricing. In Q4 2024 the company reported earnings per share of $6.19, slightly below the $6.27 estimate, while revenue rose to $735.9 million, a modest increase from prior periods but falling short of the $829.3 million estimate for Q4 2025; in that quarter EPS climbed to $7.70, surpassing the $7.33 estimate, yet revenue of $790.2 million again missed the $829.3 million forecast, indicating a pattern of earnings growth coupled with revenue shortfalls. Over the two quarters examined, EPS grew by roughly 25 % year‑over‑year, and revenue increased about 7 %, but the company has consistently beat or missed analyst expectations in alternating quarters, suggesting volatility in revenue forecasting while maintaining a positive earnings trajectory. Recent news highlights include a significant insider sale by the CEO, which may signal liquidity concerns or a shift in confidence, alongside robust clinical wins for Tyvaso and Ralinepag that reinforce growth expectations; the FDA pre‑market approval of the LungFX ex‑vivo perfusion system and the acquisition of Thymmune Therapeutics expand the company’s organ perfusion and regenerative medicine capabilities, potentially opening new revenue streams; and RBC Capital’s price‑target upgrade to $704 reflects renewed bullish sentiment tied to upcoming FDA filings for Ralinepag and Nebulized Tyvaso. Investors should watch for the Q2 2026 earnings release to assess whether the company can sustain its EPS growth trend, monitor any updates on FDA review progress for the new indications, and keep an eye on insider trading activity and regulatory milestones that could materially influence the company’s valuation and market perception.

EPS

EstBeatMiss
$5.96$6.45$6.95$7.44$7.93Q4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$7.04 - -
Q4'25$7.33$7.70+5.1%
Q4'24$6.27$6.19-1.2%

Revenue

EstBeatMiss
$722M$752M$783M$813M$843MQ4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$824M - -
Q4'25$829M$790M-4.7%
Q4'24 - $736M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

UTHR Stock Snapshot

UTHR is currently trading at $547.06, giving United Therapeutics Corporation a market cap of 23.18B and a P/E ratio of 18.0. Today's range spans $539.33–$553.86, with shares opening at $553.86 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 53/100.

Over the past year UTHR has traded between $272.12 and $609.35 - the current price is +101.0% off the 52-week low and -10.2% from the high. 24 analysts cover the stock with a Buy consensus and a mean 12-month target of $664.00 (range $516.00–$750.00), implying upside of +21.4%.

Sector rotation context matters for UTHR's HOLD phase (41/100, HOLD): in Healthcare, large-cap names (23.18B market cap) with neutral technicals and neutral sentiment (53/100) are often in a staging area ahead of a rotation trade. The current P/E ratio stands at 18.0. Price: $547.06 (in the upper portion of its 52-week range in $272.12–$609.35). When sector flows resume, names that consolidated cleanly rather than correcting sharply tend to lead the next leg - and UTHR's current setup fits that pattern.

In neutral phases, large-cap Healthcare names like UTHR are often where sector rotation debates play out quietly — at 23.18B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 41/100 (HOLD) and neutral sentiment (53/100) at $547.06 (in the upper portion of its 52-week range) describe a stock that is being considered rather than avoided.